US FDA inspection delay at Monroe plant
The Monroe facility is awaiting FDA inspection, delaying potential revenue from injectable products. Management has limited visibility on timing.
GLENMARK / Q3-FY25 / risks
Keep the risk register visible.
Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Currency headwinds in emerging markets
Adverse currency movements in LATAM, South Africa, and Russia impacted reported growth and EBITDA margins by approximately INR 71 crore in Q3.
India business slowdown in acute respiratory
Q3 India formulation growth was impacted by a slowdown in acute respiratory sales, though management expects recovery in Q4.
Competition in GLP-1 market
The Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.